Experienced in Hypercalcemia

Barbara Hero

Kerpener Str. 62, 
Koeln, NW, DE 
Clinical Trials:Currently Recruiting for 1 Trial
Experienced in Hypercalcemia
Kerpener Str. 62, 
Koeln, NW, DE 
OverviewLocationsClinical Research

Overview

Barbara Hero practices in Koeln, Germany. Ms. Hero is rated as an Experienced expert by MediFind in the treatment of Hypercalcemia. Her top areas of expertise are Neuroblastoma, Embryonal Tumor with Multilayered Rosettes, Opsoclonus-Myoclonus Syndrome, Ganglioneuroma, and Bone Marrow Transplant.

Her clinical research consists of co-authoring 96 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article in the study of Hypercalcemia.

Gender
Female

Locations

Kerpener Str. 62, Koeln, NW 50924, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Post-Authorisation Safety Study Patient Registry of Patients With High-risk Neuroblastoma Being Treated With the Monoclonal Antibody Dinutuximab Beta
A Post-Authorisation Safety Study Patient Registry of Patients With High-risk Neuroblastoma Being Treated With the Monoclonal Antibody Dinutuximab Beta
Enrollment Status: Recruiting
Publish Date: February 07, 2024
Intervention Type: Other
B-NHL 2013 - Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents
B-NHL 2013 - Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents
Enrollment Status: Active_not_recruiting
Publish Date: March 24, 2025
Intervention Type: Drug
Study Drugs: Rituximab, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin, Vindesine, Etoposide, Ifosfamide, Methotrexate, Prednisolone, Vincristine
Study Phase: Phase 3
View 1 Less Clinical Trial

96 Total Publications

International neuroblastoma risk group consortium: a model of a networking for rare cancers.
International neuroblastoma risk group consortium: a model of a networking for rare cancers.
Journal: Journal of the National Cancer Institute
Published: June 22, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Hero's expertise for a condition
ConditionClose
    View All 16 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile